PROM1 and non-small cell lung carcinoma: This step was necessary because previous studies, including one that examined 145 cases of stage I non-small cell lung cancer (NSCLC), revealed that CD133 overexpression alone was not a reliable predictor of recurrence or overall survival, in line with earlier study [26, 27].